AI-powered vocal monitoring for heart failure home care
Official title: AVATAR-HF (Artificial Voice Analysis and Telemonitoring for Heart Failure): Studio di fattibilità Sull'Uso Dell'Analisi Vocale Basata su Intelligenza Artificiale Per il Telemonitoraggio Dei Pazienti Con Insufficienza Cardiaca.
Run by Niguarda Hospital · NCT07664748 · Data updated 2026-11-12
A feasibility test to see if an AI voice-based home monitoring platform called AVATAR-SC can help people with heart failure manage their condition after hospital discharge.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Niguarda Hospital Academic / other |
| Locations | 1 site (Milan, Ita) |
| Status | Recruiting |
| Started | October 30, 2026 |
| Main results expected | May 15, 2027 |
| Study ends | May 15, 2028 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT07664748 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with heart failure (NYHA II-IV), recently discharged after acute heart failure or receiving Levosimendan in a day-hospital setting, who can use the provided device and sign consent in Italian.
✕Probably not a fit
Patients who cannot interact with the avatar, have significant phonation or cognitive impairments, or have limited life expectancy may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study tests AVATAR-SC, a home monitoring system that uses voice analysis, simple questionnaires, and AI to flag potential worsening of heart failure. It will enroll 60 adults with heart failure, split between recent post-discharge patients and those receiving Levosimendan in a day-hospital. Participants interact with a computer-generated avatar, submit short voice clips, and complete PROMs to help clinicians monitor status. The trial aims to determine feasibility, user acceptability, and adherence in a real-world home setting. Interventions include AVATAR-SC usage and Levosimendan as applicable within the study design.
Why it matters
Potential benefit: If successful, the platform could make home monitoring easier and more proactive, potentially reducing hospital readmissions for heart failure.
How similar studies have gone: Vocal biomarkers and AI-based monitoring have shown promise in small studies, but robust home-monitoring feasibility data remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Age ≥ 18 years * Diagnosis of heart failure (NYHA Class II-IV), according to the Diagnosis Related Group (DRG) classification. * Recent discharge following acute heart failure (AHF) or ongoing treatment with Levosimendan in a Day Hospital setting. * Provision of signed informed consent in Italian. * Currently receiving Guideline-Directed Medical Therapy (GDMT) for heart failure Exclusion Criteria: * Inability or incapacity to provide informed consent. * Cognitive impairment severe enough to prevent interaction with the avatar and compromise the reliability of the collected data. * Significant phonation disorders (e.g., results of previous otorhinolaryngological surgery or post-traumatic outcomes). * Inability to manage a compatible device or the device provided by the study for interaction with the AVATAR-SC platform. * Life expectancy of less than 6 months due to concurrent comorbidities. * Technological or language barriers.
Where it's running
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, Ita, Italy Recruiting
Study contacts
- Study coordinator: Alessandro Verde, MD
- Email: alessandro.verde@ospedaleniguarda.it
- Phone: +39026444
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.